CoChat

Efficacy and tolerability of vildagliptin in drug‐naïve patients with type 2 diabetes and mild hyperglycaemia*

Scherbaum, W. A., Schweizer, A., Mari, A., Nilsson, P. M., Lalanne, G., Jauffret, S., Foley, J. E. · 2008 · Diabetes, Obesity and Metabolism
Cited by 120

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Aim: This study was conducted to assess efficacy and tolerability of vildagliptin in drug‐naïve patients with type 2 diabetes and mild hyperglycaemia. Methods: Multicentre, double‐blind, randomized, placebo‐controlled, parallel‐group study of 52‐week treatment with vildagliptin (50 mg q.d.) in 306 drug‐naïve patients with type 2 diabetes (A1C = 6.2–7.5%). A1C, fasting plasma glucose (FPG) and measures of prandial glucose control and beta‐cell function determined during standard meal tests were assessed. Results: Baseline A1C and FPG averaged 6.7% and 7.1 mmol/l, respectively, in patients randomized to vildagliptin (n = 156) and 6.8% and 7.2 mmol/l in those randomized to placebo (n = 150). A1C decreased modestly in vildagliptin‐treated patients (Δ = −0.2 ± 0.1%) and increased in patients receiving placebo (Δ = 0.1 ± 0.1%). The between‐group difference (vildagliptin − placebo) in adjusted mean change (AMΔ) in A1C was −0.3 ± 0.1% (p < 0.001). FPG increased in patients receiving placebo (Δ = 0.5 ± 0.1 mmol/l) and to a significantly lesser extent in vildagliptin‐treated patients (between‐group difference in AMΔ FPG = −0.4 ± 0.2 mmol/l, p = 0.032). Relative to placebo, 2‐h postprandial glucose (PPG) decreased (−0.9 ± 0.4 mmol/l, p = 0.012), and insulin secretory rate (ISR) relative to glucose [ISR area under the curve (AUC) 0–2 h /glucose AUC 0–2 h ] increased (+5.0 ± 1.2 pmol/min/m 2 /mM, p < 0.001). Mean body weight decreased by 0.5 ± 0.3 kg in vildagliptin‐treated patients and by 0.2 ± 0.3 kg in patients receiving placebo. The side‐effect profile of vildagliptin was similar to that of placebo, and one hypoglycaemic episode occurred in one patient receiving placebo. Conclusions: In drug‐naïve patients with mild hyperglycaemia, relative to placebo, 52‐week treatment with vildagliptin 50 mg q.d. significantly decreases A1C, FPG and PPG and improves beta‐cell function without weight gain or hypoglycaemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2008.00850.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 120

Metadata

Authors
Scherbaum, W. A., Schweizer, A., Mari, A., Nilsson, P. M., Lalanne, G., Jauffret, S., & Foley, J. E.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2008-07-10
Volume
10
Issue
8
Pages
675-682
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2063976195
Cited by
120
References
4
FWCI
13.73
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and tolerability of vildagliptin in drug‐naïve patients with type 2 diabetes and mild hyperglycaemia*. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00850.x
The paper
Scherbaum, W. A., Schweizer, A., Mari, A., Nilsson, P. M., Lalanne, G., Jauffret, S., & Foley, J. E. (2008). Efficacy and tolerability of vildagliptin in drug‐naïve patients with type 2 diabetes and mild hyperglycaemia*. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00850.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.